Naomi, 50, Denied MS Treatment Due to Disease Duration: "I Don’t Want to Wait Until I’m in a Wheelchair"
Naomi, a 50-year-old Dutch woman, has been refused access to disease-modifying drugs (DMDs) for multiple sclerosis (MS) due to the lengthy duration of her condition, leaving her concerned about her future mobility.
Naomi was diagnosed with MS in 1999, making her condition one of the longest-standing cases in the Netherlands. DMDs, which slow down the progression of MS and reduce the frequency of relapses, are typically not prescribed to patients who have been living with the disease for an extended period, as they are deemed less effective.
Reflecting on her experience, Naomi expressed her disappointment and frustration with the current medical approach. She stated, "I find it unacceptable that someone with a long-term disease isn’t helped. I don’t want to wait until I’m in a wheelchair before I receive treatment."
The Dutch Health Care Institute (ZIN) and the Dutch Association of Neurology (NVN) maintain that DMDs are primarily designed for patients in the early stages of MS. However, both organizations recognize the complexity of the issue and the challenges faced by patients with long-term MS, emphasizing the importance of individual case evaluations.
Naomi’s story has sparked a conversation about the ethical implications and fairness of current treatment guidelines for patients with long-term MS. While medical advancements have significantly improved the quality of life for many MS patients, others with long-term cases face challenges accessing crucial treatments.
Related reading
- How Reading Protects Your Brain for Life: From Bedtime Stories to Book Clubs
- Air Pollution Linked to Higher Risks of Glaucoma and Cataract
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)
- Why the Four Grand Slams Didn't Share One Tiebreak Rule Until 2022 (daybreakwire.com)